免疫抑制诱导纤维化的回归在初级胆道胆炎中与中度至重的接口肝炎
Rui Wang1, Qiuxiang Lin2, Zhonghua Lu3
1Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China.
Journal of autoimmunity
|February 1, 2024
概括
与单独使用ursodeoxycholic acid (UDCA) 相比,对原发性胆道胆道炎 (PBC) 的联合治疗显著降低了肝纤维化. 基线IgG和ALP水平预测治疗反应,有助于个性化治疗选择.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 初级胆道胆炎 (PBC) 患者中度至重的接口肝炎在ursodeoxycholic acid (UDCA) 上面临肝移植和死亡的高风险.
- 新的治疗策略对于改善这一患者群体的治疗结果至关重要.
研究的目的:
- 在PBC患者中,评估联合治疗 (UDCA + 免疫抑制剂) 与UDCA单一治疗的疗效.
- 为个性化治疗方法确定治疗反应的预测因素.
主要方法:
- 一个多中心的回顾性队列研究,以前性收集来自中国的数据 (2009-2023年).
- 将166名接受联合治疗 (UDCA + IS) 的患者与32名接受UDCA单一治疗的患者进行了比较,评估了生物化学,组织学,存活率和预后.
- 研究了基线IgG和酸酶 (ALP) 作为纤维化回归的预测因素.
主要成果:
- 与UDCA单独治疗相比,组合疗法在减少肝纤维化方面显示出显著更高的疗效,回归率增加了8.3倍 (6.3%至52.4%,P <0.001).
- 生物化学标志物,生存率和整体预后也在组合治疗中得到改善.
- 基线IgG>1.3 × ULN和ALP<2.4 × ULN被确定为纤维化回归的关键预测因素.
结论:
- 与UDCA一起使用免疫抑制剂的联合治疗为中度至重度接口肝炎的PBC患者提供了改善的结果.
- 基线IgG和ALP水平是纤维化回归的显著预测指标,使预测得分 (FRS) 的发展成为可能.
- FRS得分有效地识别了可能受益于组合治疗的患者,促进了个性化治疗策略.
相关概念视频
01:17Chronic Bowel Disorders: Introduction
450
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
450
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166